Date:5/6/2009

tainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including our most recent Form 10-Q and all subsequent periodic filings made with the SEC. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

    Contact:

    Paula Izidoro
    Investor Relations
    858-410-8904

'/>"/>

SOURCE Gen-Probe Incorporated Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine news :

1. Gen-Probe Reports Financial Results for First Quarter 2009
2. Gen-Probe, Roche Prevail in Arbitration With Digene Concerning Human Papillomavirus Agreement
3. Gen-Probe Board of Directors Elects Carl Hull Chief Executive Officer
4. Tepnel Shareholders Approve Acquisition by Gen-Probe
5. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008
6. Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash
7. Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration
8. Eric Tardif Joins Gen-Probe as Senior Vice President, Corporate Strategy
9. Gen-Probe to Webcast Presentation at the 27th Annual J.P. Morgan Healthcare Conference
10. Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference
11. Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance